Focus Partners Advisor Solutions LLC Buys 6,819 Shares of Exact Sciences Corporation $EXAS

Focus Partners Advisor Solutions LLC grew its position in shares of Exact Sciences Corporation (NASDAQ:EXAS) by 82.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,135 shares of the medical research company’s stock after acquiring an additional 6,819 shares during the quarter. Focus Partners Advisor Solutions LLC’s holdings in Exact Sciences were worth $828,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in EXAS. True Wealth Design LLC boosted its holdings in Exact Sciences by 951.8% during the second quarter. True Wealth Design LLC now owns 589 shares of the medical research company’s stock worth $31,000 after purchasing an additional 533 shares during the last quarter. Westside Investment Management Inc. increased its stake in Exact Sciences by 100.0% in the 3rd quarter. Westside Investment Management Inc. now owns 542 shares of the medical research company’s stock valued at $31,000 after buying an additional 271 shares during the last quarter. Country Trust Bank bought a new position in shares of Exact Sciences during the 2nd quarter worth approximately $32,000. Quent Capital LLC bought a new position in shares of Exact Sciences during the 3rd quarter worth approximately $48,000. Finally, OFI Invest Asset Management boosted its stake in shares of Exact Sciences by 241.2% in the 3rd quarter. OFI Invest Asset Management now owns 1,085 shares of the medical research company’s stock worth $59,000 after buying an additional 767 shares during the last quarter. Hedge funds and other institutional investors own 88.82% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on EXAS. Evercore set a $105.00 price target on Exact Sciences and gave the company an “in-line” rating in a research report on Monday, January 5th. Stifel Nicolaus reissued a “hold” rating and issued a $105.00 price objective (up from $80.00) on shares of Exact Sciences in a research report on Friday, November 28th. Wells Fargo & Company restated an “equal weight” rating and issued a $105.00 price objective (up from $85.00) on shares of Exact Sciences in a research note on Thursday, November 20th. Barclays reaffirmed an “equal weight” rating and set a $105.00 target price (up from $77.00) on shares of Exact Sciences in a research report on Thursday, November 20th. Finally, Citigroup downgraded shares of Exact Sciences from a “buy” rating to a “hold” rating in a report on Thursday, November 20th. Twenty-one equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Reduce” and a consensus target price of $92.13.

Exact Sciences Stock Performance

Shares of EXAS opened at $103.50 on Friday. Exact Sciences Corporation has a 1 year low of $38.81 and a 1 year high of $103.67. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.43 and a quick ratio of 2.17. The stock’s fifty day moving average price is $102.65 and its two-hundred day moving average price is $81.87. The firm has a market cap of $19.76 billion, a PE ratio of -94.09, a PEG ratio of 2.36 and a beta of 1.41.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings results on Friday, February 13th. The medical research company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of $0.08 by ($0.29). Exact Sciences had a positive return on equity of 0.53% and a negative net margin of 6.40%.During the same period in the prior year, the company posted ($0.06) EPS. The business’s quarterly revenue was up 23.1% on a year-over-year basis. On average, equities research analysts forecast that Exact Sciences Corporation will post -0.58 EPS for the current year.

Exact Sciences Company Profile

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.